Table 2 Summary of Trials COVID-19 vaccine in autoimmune and rheumatic disease patients
Study | Design | Participants | Location | Comparator groups | Main findings |
|---|---|---|---|---|---|
COVID‑19 vaccine hesitancy in patients with systemic autoimmunerheumatic disease: an interview‑based survey [2] | Cross sectional interview based survey | 280 | Western India | 102 controls | Vaccine acceptance reported in 54% of RD patients. Patients > 45 years of age were more willing than those age < or equal to 45 years |
SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists [16] | Cross sectional interview based survey | 830 | Rome, Italy | 370 controls | No difference among patients RD diagnosis subgroups |
Acceptability of the COVID-19 Vaccine in Patients with Rheumatic Diseases and Healthcare Professionals in 19 Arab Countries [17] | Cross sectional web-based survey | 1,594 | 19 Arab countries including Algeria, Bahrain, Egypt, Iraq, Jordan, Syria and United Arab Emirates | 1,517 healthcare professionals | Acceptance to receive COVID-19 vaccine was reported by 344 (54.9%) of 626 patients with rheumatic and musculoskeletal disease, 29% of the patients were vaccinated compared to 59% of healthcare professionals |
Willingness to get the COVID-19 vaccine among patients with rheumatic diseases, healthcare workers and general population in Turkey: a web-based survey [18] | Cross sectional web-based questionnaire survey | 732 | Istanbul, Turley | 763 individuals from general population, 320 hospital workers | 29.2% of patients with RD were willing to be vaccinated, compared to 34/6% of general population and 52.5% of hospital workers |
COVID-19 Vaccine Hesitancy in Rheumatology Patients [20] | Cross sectional electronic survey | 433 | Southeastern United States | None | Rheumatology patients wanted to be vaccinated against COVID-19 at a rate that was higher than national surveys estimates at the time (85% vs 60–69%) |